Aclaris Therapeutics, Inc. (ACRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.17+3.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Aclaris is advancing its pipeline with a Phase 2 asthma trial for ATI-052. The company has shown some positive earnings beats and stable management. Its market price is about 23% below our valuation, reflecting cautious optimism. If it can improve revenue and reduce losses, it may recover.
Aclaris is currently loss-making with negative earnings and revenue expected to decline about 26% next year. Recent earnings misses and litigation risks weigh on confidence. The company faces elevated risk and uncertain cash flow, making recovery uncertain.
The market expects about a 26% revenue decline and prices the stock roughly 23% below our valuation. Our valuation is about 30% below the Street median, reflecting skepticism about near-term recovery. We see some optionality but also significant challenges ahead.
Breaks if: EPS remains below -$0.50 per share in FY27
Breaks if: Failure to initiate or significant delay in Phase 2 trial for ATI-052
Breaks if: YoY revenue growth falls below -10% in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. ACRS is currently in a watch state, with recent financial performance underwhelming compared to its peers, but management shows stability and a commitment to advancing clinical trials.
The market seems to price in a fragile situation, as ACRS carries an expensive valuation compared to peers. There is an expectations gap, indicating that the market anticipates significant future developments, but this is not fully justified given the current fundamentals.
Management has reaffirmed their ability to fund operations through 2028 and is making progress in clinical trials, which supports a stable outlook. However, recent financial performance has been weak, and the risk of missing future estimates remains elevated.
The long-term thesis hinges on the success of clinical trials for ATI-052 and ATI-2138, as well as broader healthcare sector performance. If sector leaders continue to perform well, it could positively impact ACRS, but any negative guidance or economic downturn could weigh heavily on the stock.
Over the next 1 to 3 years, ACRS faces a mix of opportunities and challenges, with management focused on key milestones but operating in a volatile environment. Not investment advice.
The most important moves since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.